Showing posts with label Vision. Show all posts
Showing posts with label Vision. Show all posts

Monday, April 11, 2011

Innovative Technique Gives Vision Researchers Insight Into How People Recognize Faces


Main Category: Eye Health / Blindness
Also Included In: Neurology / Neuroscience;  Biology / Biochemistry
Article Date: 17 Mar 2011 - 3:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
It is no surprise to scientists that the largest social network on the web is called Facebook. Identifying people by their face is fundamental to our social interactions, one of the primary reasons vision researchers are trying to find out how our brain processes facial identity.

In a study recently published in the Journal of Vision, scientists used an original approach a method that "shakes" the brain gently and repeatedly by making an image appear and disappear at a constant rate to evaluate its sensitivity to perceiving facial identity. The technique is called steady-state visual evoked potential (SSVEP).

"If we measure global human brain activity when one face is viewed, it cannot be differentiated from brain activity when another face is viewed," said author Bruno Rossion, PhD, a researcher at the Institute of Psychology and Institute of Neuroscience, Université Catholique de Louvain, Belgium. "This is why we relied on a method in which brain activity is compared between repetition of the same face and the presentation of different faces in succession."

During the experiment, 12 participants were presented with a series of faces appearing at a frequency of 3.5 faces per second. The result showed the brain signal at that specific frequency only was much larger when a sequence of different faces was presented at that rate than when an identical face was repeated.

The research team was positively surprised by the resulting large size of the difference between the two conditions, obtained only after one minute and a half of testing, and was equally astonished that the difference in conditions did not exist when the faces were inverted. The study also confirmed that the region for face perception lies primarily in the posterior part of the brain's right hemisphere.

The ability to recognize a face is a common problem in cases of sudden onset of posterior brain damage, neurodegenerative disorders like Alzheimer disease and other forms of dementia and social disorders such as autism. Rossion points out that an advantage of using this highly sensitive SSVEP methods is that it can be used and compared objectively in different human populations adults, infants, children, neurological patients, people with long-life face recognition impairments or autism - without requiring complex instructions and a long testing duration.

"Face recognition involves the most complex aspects of perception and memory and, for this reason, understanding how it works has large-scale implication," Rossion adds. "Ultimately, through a better understanding of this function, we will make tremendous progress in our understanding of how the brain works in general, develop tools to detect its dysfunction and hopefully help remedy it."

Source: Association for Research in Vision and Ophthalmology (ARVO)

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Sunday, April 10, 2011

InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Cataract Surgery

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8758.

Main Category: Eye Health / Blindness
Also Included In: Pain / Anesthetics
Article Date: 23 Mar 2011 - 9:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
InSite Vision Incorporated (OTCBB:INSV) announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. This randomized four-arm study compared once- and twice-daily doses of ISV-303 versus Xibrom™ and DuraSite® (vehicle), each administered twice-daily. ISV-303 combines a lower dose (0.075%) of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAY™/Xibrom (bromfenac ophthalmic solution) 0.09%, marketed by ISTA Pharmaceuticals) with InSite Vision's proprietary DuraSite drug delivery technology.

The Phase 1/2 clinical trial enrolled 169 patients undergoing cataract surgery. The primary endpoint of the study was the absence of cells in the anterior chamber of the eye at day 15 post surgery. Once-daily ISV-303 achieved statistically significant superiority compared to vehicle (53.3% vs. 19.0%, p=0.0016) for the primary endpoint. Further, secondary endpoints such as reduction of flare, pain and discomfort as a result of inflammation, achieved statistically significant superiority at days 8, 15 and 29 as compared with vehicle. While once-daily ISV-303 achieved a numerically superior difference in the primary endpoint versus twice-daily Xibrom (53.3% vs. 42.2%), the results did not reach statistical significance given the relatively small size of the trial. ISV-303, Xibrom and vehicle were all generally well tolerated and there were no safety concerns or serious adverse events related to any of the agents. InSite Vision intends to present a final analysis of the ISV-303 Phase 1/2 clinical trial in conjunction with a future scientific meeting.

The exploratory Phase 1/2 study was not designed to achieve statistically significant difference between the arms. Nevertheless, the results of this relatively small study comfortably demonstrate the clear efficacy and safety of once-daily ISV-303 over DuraSite in terms of a regulatory pathway, and the promise of a commercially superior once-daily NSAID for post-surgical use in the marketplace. Following final analysis, the Company plans to initiate discussions with the U.S. Food and Drug Administration (FDA) on the design of the pivotal Phase 3 program for once-daily ISV-303. The Company also plans to conduct a Phase 2 pharmacokinetic study of once-daily ISV-303 against ISTA Pharmaceutical's currently marketed once-daily NSAID, BROMDAY.

"It is a delightfully rare situation to experience such stunningly statistically significant results in an exploratory Phase 1/2 study," said Timothy Ruane, Chief Executive Officer of InSite Vision. "With the efficacy and safety profile established in this study, and potential patent protection extending to 2029, we believe once-daily ISV-303 is very well positioned to compete in the growing $300 million ophthalmic NSAID market in the United States. Importantly, the results of this study further transform InSite Vision into a late-stage company with three Phase 3 candidates that we intend to move toward approval."

InSite Vision is advancing another product candidate that utilizes a low-concentration of bromfenac enabled by DuraSite. ISV-101, a lower dose of bromfenac in DuraSite, is being developed for the treatment of dry eye disease. On January 11, 2011, InSite Vision announced it had filed an Investigational New Drug (IND) application for ISV-101 with the FDA. The Company is now positioned to initiate a dose-ranging Phase 1/2 clinical trial in 2011 to evaluate the safety and efficacy of ISV-101 when administered to patients suffering from dry eye disease. Patent protection for this drug candidate is also expected to extend into 2029. Preclinical data on the safety of ISV-303 and ISV-101 (bromfenac formulated in DuraSite) on ocular tissues have been accepted for presentation at the 2011 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1 - 5, 2011 in Fort Lauderdale, Florida.

Cataract surgery is the most frequently performed ocular surgery in the United States with more than three million procedures annually. Following surgery, anti-inflammatory eye drops are typically prescribed to reduce pain and inflammation and to enhance healing.

Dry eye disease occurs when the surface of the eye becomes compromised for various reasons, frequently involving tear-film changes. While causes of dry eye may vary, it is frequently associated with inflammation of the surface of the eye, the lacrimal gland, and/or the conjunctiva. A potentially chronic condition that can occur at any age, dry eye disease is most prevalent among the elderly. It is estimated to affect at least twenty-five million people in the U.S. alone.

About DuraSite®

InSite's DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. InSite vision is also applying DuraSite to multiple other clinical- and preclinical-stage product candidates to create a portfolio of novel ophthalmic products.

Source:
InSite Vision

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Dow Corning And The Centre For Vision In The Developing World Launch Children's Vision Correction Initiative


Main Category: Eye Health / Blindness
Also Included In: Pediatrics / Children's Health
Article Date: 18 Mar 2011 - 4:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
4 stars5 stars
Dow Corning, a global leader in silicon-based technology, and the Centre for Vision in the Developing World (CVDW) are jointly announcing a collaboration to create an innovative new way to help correct the vision of children in the developing world. Dow Corning has committed US $3 million of funding and materials expertise to the CVDW as part of this collaboration to launch an initiative called Child ViSion™.

The Child ViSion™ initiative will design, manufacture and distribute a child-specific version of self-adjustable eyeglasses to children in the developing world. The aim is to increase the effectiveness of classroom-based education by improving children's ability to see the blackboard from which they are being taught.

"There are 100 million children or more in the developing world who need glasses to benefit fully from their education in the classroom. This problem arises principally because there are too few eye care professionals in the developing world," said Prof. Josh Silver, Oxford University physicist, founder and director of the CVDW, and inventor of the world's first universal fluid-filled adjustable eyeglasses. "Through this collaboration with Dow Corning, CVDW can now expand our efforts to provide eyeglasses to the children who need them for their education."

The goal of the CVDW, a United Kingdom-based Community Interest Company, is to improve vision for people in the developing world who lack access to adequate vision correction.

"This collaboration between Dow Corning and the Centre for Vision in the Developing World will combine our expertise to help bring improved vision correction to children in desperate need," said Stephanie A. Burns, Chairman and CEO of Dow Corning.

Through Child ViSion™, Dow Corning will work with the CVDW to explore how self-adjustable eyeglasses can be designed specifically for the needs of children so that the glasses are able to withstand daily use, are light weight and look more appealing, which will increase the likelihood that they will be worn. Another key element of the initiative will be to ensure the design can be scaled up to mass-production levels, which includes lowering the cost of production.

"Dow Corning fluids played a critical role in Prof. Silver's pioneering self-adjustable glasses, which have already provided vision correction to approximately 40,000 people in more than 20 countries," said James Stephenson, Dow Corning global Healthcare marketing manager and leader of the Child ViSion™ initiative at Dow Corning. "We are excited to further our relationship with the CVDW and to see how our silicon-based technologies can now improve vision correction and the quality of life for children in the developing world."

Note

Prof. Silver's original self-adjustable glasses contain special lenses composed of clear membranes that are filled with Dow Corning silicone fluid. By adding or removing fluid via a removable syringe and dial attached to the glasses' frame, wearers can modify the curvature of the lenses and therefore the strength of their glasses. The glasses are designed to provide vision correction for myopia (nearsightedness), hyperopia (farsightedness) and presbyopia (inability to focus on near objects).

Source:
Dow Corning
Centre for Vision in the Developing World

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Saturday, April 9, 2011

Retina Implant AG Partners With Wills Eye Institute To Bring Artificial Vision Clinical Trials To The United States


Main Category: Eye Health / Blindness
Also Included In: Clinical Trials / Drug Trials
Article Date: 20 Mar 2011 - 0:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
5 stars5 stars
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site. This partnership marks the first time Retina Implant's subretinal implant technology will be utilized in studies by patients who suffer from retinitis pigmentosa in North America.

"The results of the subretinal approach in Europe demonstrate the great potential this implant has to impact dramatically the quality of life for our patients here in the United States," said Dr. Julia A. Haller, ophthalmologist-in-chief, Wills Eye Institute. "Patients involved in previous clinical trials have achieved extraordinary success in their ability to regain useful vision. It is this life-changing success we hope to replicate with our own patients as Wills becomes the first institution in the U.S. to offer Retina Implant's technology."

Retina Implant's subretinal implant technology has been in clinical trials for more than six years in Germany and plans to expand its second human clinical trial into the U.K. this summer. The results of their first human clinical trial proved to be superior to any other company in the retinal implant industry. Moreover, results of Retina Implant's first human clinical trial were published in the prestigious peer-reviewed journal Proceedings of the Royal Society B last November. The results showed placement of the implant below the retina, in the macular region, provided optimum visual results allowing patients to recognize foreign objects and to read letters to form words.

"We are honored to work with one of the foremost eye care centers in the world to bring our product to the United States," said Dr. Walter-G. Wrobel, president and CEO, Retina Implant AG. Reinhard Rubow, executive vice president and CFO, Retina Implant AG adds: "It is our hope that by offering patients in America with this technology that we, with the Wills Eye Institute, will be able to change the lives of those who are currently living in darkness."

Wills Eye Institute was established in 1832 as the nation's first eye care hospital and is recognized as a world-leader in the field of ophthalmology. Wills Eye has been ranked as one of the nation's top three ophthalmology centers by the annual U.S. News & World Report survey since its inception in 1990, and provides a full-range of primary and sub-specialty eye care. Wills Eye is the only center in North America that will conduct this evaluation of artificial vision.

"Wills Eye Institute has a strong tradition of innovation and discovery, providing people who suffer from eye disorders with cutting-edge technology that can assist them in living the best possible life," said Joseph P. Bilson, executive director, Wills Eye Institute. "We're excited to be working with Retina Implant and continue our tradition by bringing this technological advance to people in the United States who have lost their vision due to retinitis pigmentosa."

Source:
Wills Eye Institute
Retina Implant AG

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Thursday, April 7, 2011

Testing Alterations In Night Vision

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8760.

Main Category: Eye Health / Blindness
Also Included In: IT / Internet / E-mail;  Medical Devices / Diagnostics
Article Date: 25 Mar 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
Researchers from the Department of Optics of the University of Granada, belonging to the Laboratorio de Ciencias de la Vision y Aplicaciones, have developed a programme for testing alterations in night vision, and the tool required to implement it, which has been named "halometer".

This instrument consists of software named Software Halo v1.0, and a computer where the mouse is used as a response button, and a chin cup with a forehead holder to fix the observer's position. Software Halo v1.0 was initially presented as freeware available on LabVisGra's website and at the University of Granada's institutional repository. Nevertheless, it was recently released by the Free-Software Bureau of the University of Granada so, it has become a scientific freeware application.

This software was developed by a group coordinated by Rosario González Anera, receiving technical support of the Granadian company Seven Solutions and of an ophthalmological clinic set in Madrid and named Novovision. The research group was integrated by researchers José Juan Castro, Carolina Ortiz and Aixa Alarcón, and receives fundings from the regional government of Economy, Innovation and Science of the Junta de Andalucía.

Low-Light Conditions

Before the test, researchers fix the observer's position with a chin cup and a forehead holder at an adequate distance from the monitor where the test will be displayed and considering the angular diameter that light stimuli must have. The test is performed under low-light conditions (in a dark room) and, before the test, patients are given some minutes to adapt to darkness.

This test involves showing a bright light stimulus to the subject against a dark background and, progessively showing different peripheral light stimuli - with lower brightness around the central, at random, in different positions and at different distances. Subjects' task is to press the buttom of a mouse every time they detect a peripheral stimulus. Once the test ends, the software makes an estimation of a parameter named "Visual Disturbance Index" that, together with the results graphic, determines the type and intensity of visual disturbance.

This index scores from 0 to 1, so the higher is this index, the stronger is the influence of the halo or any other visual disturbance perceived by the observer. Therefore, the lower is the subject's ability to detect the peripheral stimuli displayed around the main stimulus that causes such disturbances.

One of the advantages of the halometer developed at the University of Granada is that it allows to configure such test parameters as: Special parameters: the radius of the central stimulus and the peripheral stimuli can be modified. Furthermore, the number of semi-major axes where the peripheral stimuli will be displayed can be fixed, as well as the maximum radius - maximum distance between these stimuli-, and the number of stimuli per semi-major axe. Temporary Parameters: the software allows to set some exposure time for adaptation to darkness and to the brightness of the central stimulus. Furthermore, others parameters as the exposure time to the stimulus and the time elapsed between a stimulus and the next one can also be set. The software also allows to set the color and brightness of central and peripheral stimuli, and the weight and number of times each peripheral stimulus is shown. This test has been tried with different observer groups consisting of people operated on cataract or submitted to refractary eye surgery, with normal observers and patients with different eye pathologies as AMD (Age-related Macular Degeneration) and unilateral keratitis. The results obtained showed that, in the case of patients with keratitis, the visual disturbance index for the healthy eye was found to be lower than that for the unhealthy eye, and even lower under binocular vision conditions. However, visual disturbance indexes proved to be higher in the case of patients operated on cataracts, showing a higher influence of halos and, therefore, lower detection capacity. Patients operated with LASIK refractory eye surgery also presented high vision disturbance indexes in comparison to normal observers. The results obtained with this halometer and the new software have been presented in different national and international conferences as the IX Reunión Nacional de Optica, Galice and the Wavefront Confress 2009. Furthermore, a research article has been published in the international journal Applied Optics describing the results obtained with patients operated on for refractory eye surgery. It has also been recently admitted for publication in the prestigious scientific journal Journal of Biomedical Optics, where the results obtained with patients with different eye pathologies are described.

This press release is available in French and Spanish.

Source:
José Juan Castro
University of Granada

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Fish Oil Omegas Now Fight Women's Vision Loss


Editor's Choice
Academic Journal
Main Category: Eye Health / Blindness
Article Date: 15 Mar 2011 - 9:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
3 and a half stars4 stars
It has long been known and recommended that we all include more omega-3 fatty acids in our diets. Maybe you follow the Mediterranean Diet that has a great reputation for providing these essential elements or you just love your fish and get what your body needs from the sea. No matter what source you use, this week more support for this eating behavior has justified the movement. It has now been proven that women who get lots of omega-3 fatty acids are less likely to develop age-related macular degeneration (AMD), an eye disease affecting millions of older adults in the U.S.

AMD is caused by abnormal blood vessel growth behind the retina or breakdown of light-sensitive cells within the retina itself, both of which can cause serious vision impairment. Some 1.7 million Americans have severe vision loss due to the disease, making it the leading cause of blindness in older adults.

Researchers looked at all food sources of the important fatty acids, the risk of AMD was 38% lower in women with the top one-third DHA intake compared to those with the bottom one-third intake. For those who got a lot of EPA, the risk was 34% smaller.

Cold-water oceanic fish oils are rich in DHA. Most of the DHA in fish and complex organisms with access to cold-water oceanic foods originates in photosynthetic and heterotrophic microalgae, and becomes increasingly concentrated in organisms, as they move up the food chain.

Interesting enough, fish do not naturally produce EPA, but obtain it from the algae they consume. It is available to humans from some non-animal sources (e.g., commercially, from microalgae). Microalgae are actually now being developed as a commercial source. Microalgae, and supplements derived from it, are excellent alternative sources of EPA and other fatty acids, since fish often contain other toxins due to human pollution.

William G. Christen of the Brigham and Women's Hospital in Boston states:

"Other than giving up cigarette smoking or never starting smoking, there are no known ways to prevent AMD. We also looked at the food intake of (just) fish and the data were consistent there."

Christen and colleagues used data from earlier research called the Women's Health Study, in which women 45 years and up had filled out extensive diet questionnaires. It may be a bit too early to recommend that people start supplementing their diet with fish or with fish oil supplements to stave off eye disease only because one can't rule out the possibility that women who got lots of omega-3s were simply healthier people.

After 10 years of study, 235 out of 38,022 women had developed AMD severe enough to damage their vision.

Omega-3 fatty acids are considered essential fatty acids. They are necessary for human health but the body can't make them; you have to get them through food. Omega-3 fatty acids can be found in fish, such as salmon, tuna, and halibut, other seafood including algae and krill, some plants, and nut oils. Also known as polyunsaturated fatty acids (PUFAs), omega-3 fatty acids play a crucial role in brain function as well as normal growth and development. They have also become popular because they may reduce the risk of heart disease. The American Heart Association recommends eating fish (particularly fatty fish such as mackerel, lake trout, herring, sardines, albacore tuna, and salmon) at least 2 times a week.

Source: The Archives of Opthamology

Written by Sy Kraft, B.A.
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here